Jann Harberts, Malte Siegmund, Emma Wollesen, Caroline Viola, Kim Krieg, Ole Pless, Roey Elnathan, Robert Zierold, Robert H. Blick, Nicolas H. Voelcker
{"title":"Fast-Track to Functional Neurons: Accessible and Minimalistic Neurogenin 2 Programming of Human iPSCs","authors":"Jann Harberts, Malte Siegmund, Emma Wollesen, Caroline Viola, Kim Krieg, Ole Pless, Roey Elnathan, Robert Zierold, Robert H. Blick, Nicolas H. Voelcker","doi":"10.1002/anbr.202500221","DOIUrl":null,"url":null,"abstract":"<p>Neuronal differentiation of human induced pluripotent stem cells (hiPSCs) is a cornerstone for advancing neuroscience research and therapeutic applications. However, conventional differentiation protocols are commonly resource-intensive, technically complex, and overall time-consuming—often requiring several weeks to months to yield functional neurons. Here, a streamlined method is presented to enable fast and reliable neurogenin 2 (NGN2)-mediated neuronal differentiation by introducing the “colony-initiated differentiation” (CID) approach. The CID method yields functional neurons from a commercially available hiPSC line (BIONi010-C-13, equipped with a doxycycline (DOX)-inducible NGN2 expression cassette) in just five days. Within the first two days of CID, the colonies undergo a structural reorganization, after which the cells are replated and mature for additional 3–5 days. The neurons become functional from day five onward, demonstrated by patch clamp recordings of action potentials. Critically, CID operates entirely feeder cell- and growth factor-free. Simplicity, regular-workday compatibility, and quality of the differentiation method using a market-available hiPSC line make the method easily accessible to researchers across various fields. Thus, this work not only has implications for accelerating research in toxicity screening and drug discovery but particularly in multidisciplinary fields such as materials science and bioengineering, providing a robust platform to study neuron–material interfaces and interactions.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"6 4","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500221","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anbr.202500221","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Neuronal differentiation of human induced pluripotent stem cells (hiPSCs) is a cornerstone for advancing neuroscience research and therapeutic applications. However, conventional differentiation protocols are commonly resource-intensive, technically complex, and overall time-consuming—often requiring several weeks to months to yield functional neurons. Here, a streamlined method is presented to enable fast and reliable neurogenin 2 (NGN2)-mediated neuronal differentiation by introducing the “colony-initiated differentiation” (CID) approach. The CID method yields functional neurons from a commercially available hiPSC line (BIONi010-C-13, equipped with a doxycycline (DOX)-inducible NGN2 expression cassette) in just five days. Within the first two days of CID, the colonies undergo a structural reorganization, after which the cells are replated and mature for additional 3–5 days. The neurons become functional from day five onward, demonstrated by patch clamp recordings of action potentials. Critically, CID operates entirely feeder cell- and growth factor-free. Simplicity, regular-workday compatibility, and quality of the differentiation method using a market-available hiPSC line make the method easily accessible to researchers across various fields. Thus, this work not only has implications for accelerating research in toxicity screening and drug discovery but particularly in multidisciplinary fields such as materials science and bioengineering, providing a robust platform to study neuron–material interfaces and interactions.
期刊介绍:
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.